Fundamental Analysis of United Therapeutics Corp. - Growth / Value Index


UTHR - Valuation Highlights

Valuation Analysis

   Undervalued - Price to Intrinsic Value of 0.096
   Price to Earning Ratio is 12.76 and EV to EBITDA is 8.24 suggesting company is undervalued.
   Tremendous increasing in Book Value last 3 year
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning 12.97 15.15 -17.17 %
Price to Book 2.47 2.28 -17.87 % 2.55
Price to Sales 5.45 6.18 -9.98 %
Enterprise Value to EBITDA Multiple 8.38 13.01 2.37 %


UTHR - Profitability Highlights

Profitability Analysis

   Tsr Profitability Index - Good Score of 79.38
   Gives Dividend Yield of 6.35 %
   Earning Yield of 7.84 %
   Excellent Net Margin for last 3 years
   Excellent QoQ /QoQ FY EPS growth
   Company Earning excess return
   During the past twelve months, the company has given a strong Net Margin of 42.05%
   All key Trailing Twelve Months Margin growing by 15 %
   Piotroski F Score - Stable Value of 5.0
   Annual Net Profit in last 3 years is trending up
   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   Steady Growth in EPS for last four quarters
   Good Return On Capital Employed of 13.46
   Good Return on Equity of 19.05% is achieved by the company
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 19.05 15.03 -0.843 % 5.74
Return On Asset 15.58 12.55 4.34 % 4.72
Net Profit Margin 42.05 40.82 8.68 % 45.24
Operating Profit Margin 50.31 49.92 -1.34 % 52.57
EBITDA Margin 55.70 45.77 -14.31 % 62.99


Highlights
Market Cap12167.96 M
Enterprise Value11660.26 M
Price/Book TTM2.47
Outstanding Share44366.50 K
Float/ Outstanding Share91.61%
Dividend Yield6.35 %
Share Holding
Guru Numbers
Price/Graham No1.15
Peter Lynch Ratio1.60
Piotroski F Score5.00
Altman Z Score8.56
Sloan Ratio-0.0078
Peter Lynch Fair Value0


UTHR - Growth Highlights

Growth Analysis

   Short term positive trend in total sale and net profit
   Tremendous increasing trend in total sale last 3 year
   Quarterly sales in last 5 years is trending up
   Steady increase in Total Assets for last 3 Years
   Tsr Growth Index - Poor Score of 26.72
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 2498.30 M 13.84 % 10.25 %
Gross Profit 2220.20 M 9.77 % 11.24 %
EBITDA 1391.50 M 2.45 % 31.68 %
Net Profit 1050.50 M 23.72 % 41.23 %
EPS 21.15 20.73 % NA


UTHR - Stability Highlights

Stability Analysis

   Tsr Stability Index - Excellent Score of 85.94
   Altman Z Score of 8.46 suggests good Stability
   Debt to equity ratio has decreased and is lowest in last three years
   Cash ratio of 3.72
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio 0.117 -29.87 % 0.112
Cash Ratio 3.72 -55.00 %
Quick Ratio 4.28 -55.24 % 3.64
Shareholders Equity 83.50 5.23 %
Debt to EBITDA 0.694 -10.31 %


Historical Valuation Ratios of United Therapeutics Corp.

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of United Therapeutics Corp.

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of United Therapeutics Corp.

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of United Therapeutics Corp.

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)